114 related articles for article (PubMed ID: 12805677)
1. Lactococcus lactis, a tool for the delivery of therapeutic proteins treatment of IBD.
Steidler L
ScientificWorldJournal; 2001 May; 1():216-7. PubMed ID: 12805677
[TBL] [Abstract][Full Text] [Related]
2. Lactococcus lactis carrying the pValac eukaryotic expression vector coding for IL-4 reduces chemically-induced intestinal inflammation by increasing the levels of IL-10-producing regulatory cells.
Souza BM; Preisser TM; Pereira VB; Zurita-Turk M; de Castro CP; da Cunha VP; de Oliveira RP; Gomes-Santos AC; de Faria AM; Machado DC; Chatel JM; Azevedo VA; Langella P; Miyoshi A
Microb Cell Fact; 2016 Aug; 15(1):150. PubMed ID: 27576902
[TBL] [Abstract][Full Text] [Related]
3. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.
Steidler L; Hans W; Schotte L; Neirynck S; Obermeier F; Falk W; Fiers W; Remaut E
Science; 2000 Aug; 289(5483):1352-5. PubMed ID: 10958782
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of intestinal inflammation in IL-10 deficient mice by a plasmid carrying Lactococcus lactis strain.
Zurita-Turk M; Mendes Souza B; Prósperi de Castro C; Bastos Pereira V; Pecini da Cunha V; Melo Preisser T; Caetano de Faria AM; Carmona Cara Machado D; Miyoshi A
BMC Biotechnol; 2020 Jul; 20(1):38. PubMed ID: 32703192
[TBL] [Abstract][Full Text] [Related]
5. Invasive Lactococcus lactis producing mycobacterial Hsp65 ameliorates intestinal inflammation in acute TNBS-induced colitis in mice by increasing the levels of the cytokine IL-10 and secretory IgA.
da Cunha VP; Preisser TM; Santana MP; Machado DCC; Pereira VB; Miyoshi A
J Appl Microbiol; 2020 Nov; 129(5):1389-1401. PubMed ID: 32473073
[TBL] [Abstract][Full Text] [Related]
6. Delivery of therapeutic proteins through Lactococcus lactis.
Neirynck S; Steidler L
Biotechnol Genet Eng Rev; 2006; 22():253-66. PubMed ID: 18476334
[No Abstract] [Full Text] [Related]
7. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
8. Immunology. Therapeutic manipulation of gut flora.
Shanahan F
Science; 2000 Aug; 289(5483):1311-2. PubMed ID: 10979858
[TBL] [Abstract][Full Text] [Related]
9. Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis.
Carvalho RD; Breyner N; Menezes-Garcia Z; Rodrigues NM; Lemos L; Maioli TU; da Gloria Souza D; Carmona D; de Faria AM; Langella P; Chatel JM; Bermúdez-Humarán LG; Figueiredo HC; Azevedo V; de Azevedo MS
Microb Cell Fact; 2017 Feb; 16(1):27. PubMed ID: 28193209
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive review and update on Crohn's disease.
Gajendran M; Loganathan P; Catinella AP; Hashash JG
Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory bowel disease in children--clinical, endoscopic, radiologic and histopathologic investigation.
Seo JK; Yeon KM; Chi JG
J Korean Med Sci; 1992 Sep; 7(3):221-35. PubMed ID: 1285921
[TBL] [Abstract][Full Text] [Related]
12. Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis.
Rottiers P; De Smedt T; Steidler L
Int Rev Immunol; 2009; 28(6):465-86. PubMed ID: 19954359
[TBL] [Abstract][Full Text] [Related]
13. Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci.
Bermúdez-Humarán LG; Motta JP; Aubry C; Kharrat P; Rous-Martin L; Sallenave JM; Deraison C; Vergnolle N; Langella P
Microb Cell Fact; 2015 Feb; 14():26. PubMed ID: 25889561
[TBL] [Abstract][Full Text] [Related]
14. Microbial therapeutics for acute colitis based on genetically modified Lactococcus lactis hypersecreting IL-1Ra in mice.
Namai F; Shigemori S; Ogita T; Sato T; Shimosato T
Exp Mol Med; 2020 Sep; 52(9):1627-1636. PubMed ID: 32989233
[TBL] [Abstract][Full Text] [Related]
15. IL-10 in humans: lessons from the gut, IL-10/IL-10 receptor deficiencies, and IL-10 polymorphisms.
Engelhardt KR; Grimbacher B
Curr Top Microbiol Immunol; 2014; 380():1-18. PubMed ID: 25004811
[TBL] [Abstract][Full Text] [Related]
16. Human adipose-derived stem cells attenuate inflammatory bowel disease in IL-10 knockout mice.
Jung WY; Kang JH; Kim KG; Kim HS; Jang BI; Park YH; Song IH
Tissue Cell; 2015 Feb; 47(1):86-93. PubMed ID: 25544730
[TBL] [Abstract][Full Text] [Related]
17. Germ therapy with IL-10 to treat inflammatory bowel diseases.
Michie C
Mol Med Today; 2000 Nov; 6(11):416. PubMed ID: 11074364
[No Abstract] [Full Text] [Related]
18. Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease).
Ruther U; Nunnensiek C; Muller HA; Bader H; May U; Jipp P
Hepatogastroenterology; 1998; 45(21):691-9. PubMed ID: 9684118
[TBL] [Abstract][Full Text] [Related]
19. Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice.
Nishitani Y; Tanoue T; Yamada K; Ishida T; Yoshida M; Azuma T; Mizuno M
Int Immunopharmacol; 2009 Nov; 9(12):1444-51. PubMed ID: 19733697
[TBL] [Abstract][Full Text] [Related]
20. Actobiotics as a novel method for cytokine delivery.
Steidler L; Rottiers P; Coulie B
Ann N Y Acad Sci; 2009 Dec; 1182():135-45. PubMed ID: 20074282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
